Merck's potential Novo Nordisk challenger doesn't impress analyst
A new drug candidate edged out others on weight-loss metrics in a study against fatty liver disease, but one analyst says the real winners remain ”big incumbents, Lilly and Novo.”
By MarketWire, translated by Daniel Pedersen
Tuesday, US-based pharmaceutical company Merck, known as MSD outside North America, announced new data from a drug candidate that could potentially also help people with obesity lose weight.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Denmark warns of Novo Nordisk diabetes drug shortage
For subscribers
